WILMINGTON, DE — AOP Health US, LLC announced that Rapiblyk® (landiolol), a recently introduced critical care therapy, is now more widely available nationwide through a contract with Vizient®, the country’s largest provider-driven healthcare performance improvement company.
The agreement places Rapiblyk in the Vizient catalog, expanding hospital and health system access to the medication and providing participating clients with enhanced flexibility, tiered pricing opportunities and streamlined ordering processes.
Company officials described the contract as a significant step in strengthening distribution of the therapy in high-acuity settings.
“This represents an important milestone in ensuring that Rapiblyk availability is secured nationwide, supporting clinicians and healthcare providers in critical care environments,” said John Kimmet, General Manager of AOP Health US. “We’re reinforcing our commitment to making Rapiblyk accessible where it’s needed most.”
Rapiblyk is an ultra-short-acting, selective beta-1 adrenergic receptor blocker approved by the U.S. Food and Drug Administration for the short-term reduction of ventricular rate in adults with supraventricular tachycardia or irregular rapid heart rate, including atrial fibrillation and atrial flutter, in critical care settings.
AOP Health US previously announced the drug’s commercial availability in the United States. The expanded access through Vizient is expected to further integrate Rapiblyk into hospital formularies and critical care protocols across the country.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.